A federal appeals court has dealt a major blow to abortion access nationwide by blocking the mailing of mifepristone, a key abortion pill, and requiring all dispensing to happen in-person at clinics.
The unanimous ruling Friday by a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals invalidates FDA regulations that allowed telemedicine prescriptions and mail-order pharmacy delivery of the drug. The decision takes effect immediately.
“This is a catastrophic setback for reproductive freedom,” said Dr. Jennifer Kaleba, a reproductive health policy expert at the Guttmacher Institute. “Millions of patients who rely on telehealth for abortion care now face severe barriers.”
Immediate Impact on Abortion Access
The ruling directly impacts the most common method of abortion in the United States, as medication abortion accounts for over half of all abortions. Mifepristone, typically used in combination with misoprostol, is FDA-approved for up to 10 weeks of pregnancy.
“The 5th Circuit’s decision effectively turns back the clock to pre-pandemic restrictions,” said Sarah Weiner, a senior attorney at the Center for Reproductive Rights. “It ignores both scientific evidence and the FDA’s own expert judgment.”
Background
The case stems from a lawsuit filed by anti-abortion medical groups and doctors challenging FDA approval of mifepristone. In April 2023, a Texas federal judge suspended the FDA's approval, but the Supreme Court allowed mifepristone to remain on the market while appeals played out.
The 5th Circuit’s latest ruling does not overturn FDA approval but narrows how the drug can be distributed. The FDA had permanently lifted the in-person dispensing requirement in 2021, allowing certified pharmacies to mail the drug after remote consultations.
“The FDA spent years reviewing safety data and concluded that additional restrictions were not medically necessary,” said Professor Linda Green, a health law expert at Columbia University. “The court has substituted its own judgment for that of the agency.”
What This Means
For patients, the ruling means they must travel to a clinic or doctor’s office to obtain mifepristone in person, even if they previously could get it by mail. This will disproportionately affect rural residents, those with limited transportation, and states with fewer abortion providers.
The decision also threatens telemedicine abortion services that have expanded dramatically since 2020. “We are seeing a return to the pre-Roe era of forced travel and clinic overcrowding,” said Dr. Kaleba.
Legal experts expect an emergency appeal to the Supreme Court, but the conservative-leaning judiciary may uphold the 5th Circuit’s reasoning. “The battle over mifepristone is far from over,” said Professor Green. “This ruling is likely the beginning, not the end, of a prolonged legal conflict.”
Broader Implications
The ruling adds to a patchwork of state laws, with some states already banning or severely restricting abortion. The Biden administration has vowed to defend FDA authority and may seek to intervene quickly.
“The Justice Department is exploring all options,” said a White House spokeswoman who spoke on condition of anonymity. “President Biden is committed to ensuring access to safe, legal abortion.”
Meanwhile, major pharmacy chains like CVS and Walgreens had just begun to dispense mifepristone after certification. Those plans are now on hold.
“We are evaluating the decision and its impact on our operations,” a Walgreens spokesperson said. “Patient safety and compliance with the law remain our top priorities.”
What Happens Next
The 5th Circuit’s ruling can be challenged through a full court review or direct appeal to the Supreme Court. Anti-abortion groups applauded the decision. “Today’s ruling protects women from dangerous drugs and holds the FDA accountable,” said Mary O’Connor of the Christian Legal Society.
But abortion providers warn of immediate chaos. “Patients are already calling in panic,” said Dr. Katie Moore, an OB-GYN in Louisiana. “We are bracing for an influx of people who will now have to cross state lines.”
For now, the ruling stands as one of the most significant legal restrictions on medication abortion since the Supreme Court overturned Roe v. Wade in 2022.